Vipul Patel, MD
Medical Oncology · Ocala, FLNPI 1841347655
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $16,874 of the $27,756 with a category attached, or 60.8%. 60 manufacturers reported payments, led by Activ Surgical, Inc. at 35.1% of the total. Reporting peaked in 2022 at $12,227 and has fallen 79.1% since, to $2,557 in 2025.
Across 897 payments — averaging $30.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Activ Surgical, Inc.$10K
- Novartis$2K
- E.r. Squibb & Sons, L.L.C.$1K
- Johnson & Johnson$991
- AstraZeneca$910
- Pfizer$894
- plus $12K from 54 others
Across 24 payments — averaging $6952.29 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$145K
- E.r. Squibb & Sons, L.L.C.$20K
- Eli Lilly$2K
What the payments were for
- Consulting fees$9,75035%
- Speaking & faculty fees$2501%
- Food & beverage$16,87461%
- Education$1851%
- Other$6983%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ActivSight$9,750
- GAVRETO$250
- Reblozyl$249
- NURTEC ODT$135
- OCTAGAM IMMUNE GLOBULIN (HUMAN)$111
How this compares
$27,756 in reported general payments places this provider in the 75th percentile of 507 medical oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 72 | $1,368,872 |
| BrukinsaZanubrutinib | 25 | $376,398 |
| PomalystPomalidomide | 16 | $348,281 |
| JakafiRuxolitinib Phosphate | 20 | $345,764 |
| CalquenceAcalabrutinib Maleate | 23 | $336,062 |
| NerlynxNeratinib Maleate | 15 | $323,872 |
| PromactaEltrombopag Olamine | 27 | $289,779 |
| IbrancePalbociclib | 17 | $249,933 |
| TasignaNilotinib Hcl | 13 | $248,866 |
| LynparzaOlaparib | 16 | $242,771 |
| VerzenioAbemaciclib | 12 | $176,950 |
| GilotrifAfatinib Dimaleate | 12 | $137,698 |
| EliquisApixaban | 73 | $55,816 |
| XareltoRivaroxaban | 14 | $16,384 |
| Abiraterone Acetate | 16 | $15,747 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $819 | $1,368,87272 claims |
| AstraZenecaCalquence, Lynparza | $910 | $578,83339 claims |
| NovartisPromacta, Tasigna | $1,933 | $538,64540 claims |
| Beigene USA, Inc.Brukinsa | $118 | $376,39825 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $1,027 | $348,28116 claims |
| Incyte CorporationJakafi | $394 | $345,76420 claims |
| Puma Biotechnology, Inc.Nerlynx | $49 | $323,87215 claims |
| PfizerIbrance, Eliquis | $894 | $305,74990 claims |
| Lilly USA, LLCVerzenio | $303 | $176,95012 claims |
| Boehringer IngelheimGilotrif | $202 | $137,69812 claims |
| Johnson & JohnsonXarelto | $991 | $16,38414 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 507 medical oncology providers in Florida.
Other medical oncology in Ocala
- Ketan DoshiOcala$119K
- Rama BalaramanOcala$95K
- Anju VasudevanOcala$65K
- Neil LoveMiami$5.6M
- Mahdi TahaBoca Raton$1.7M
- Raji ShameemOrlando$1.3M
- Mohammad JahanzebBoca Raton$1.3M
- Michel VelezOrlando$927K
- Yuanbin ChenOrlando$810K
- Reshma MahtaniPlantation$608K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.